Parathyroid Hormone Analog Drug Class List

Drugs in Drug Class: Parathyroid Hormone Analog

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	BONSITY	teriparatide	SOLUTION;SUBCUTANEOUS	211939-001	Oct 4, 2019		RX	No	No
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-002	Jun 25, 2008	AP	RX	Yes	Yes
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-001	Nov 26, 2002		DISCN	No	No
Apotex	TERIPARATIDE	teriparatide	SOLUTION;SUBCUTANEOUS	211097-001	Nov 16, 2023	AP	RX	No	No
Teva Pharms Usa	TERIPARATIDE	teriparatide	SOLUTION;SUBCUTANEOUS	208569-001	Nov 16, 2023	AP	RX	No	No

Last updated: June 17, 2026

Parathyroid Hormone Analog market dynamics and patent landscape: key drugs, exclusivity timelines, and generic/biosimilar entry risk

Parathyroid hormone analogs are a small, high-value endocrine segment where patent estates and device-adjacent manufacturing know-how drive long launch delays for oral generics (in practice, most competitors are development-stage peptides or biosimilar-like analogs rather than true generics). The patent landscape is concentrated around a handful of marketed peptide injections and their device/formulation/process claims, with exclusivity layered by regulatory data protection, pediatric extensions, and in some cases method-of-use claims. Commercial risk for new entrants is dominated by (1) expiration sequencing across composition and process patents, (2) whether the product is treated as a biologic or as a chemical drug for regulatory exclusivity purposes, and (3) litigation and settlement history that can restrict “at-risk” launches.

Market structure in this class (what matters for IP and launch timing)

• These are peptide therapeutics administered by injection (daily or weekly), with dose titration and route-specific product claims.
• Competition tends to be “same-moA, different product” rather than interchangeable small-molecule generics.
• Patent estates usually span:
  • Composition of matter (the analog sequence, substitutions, cyclization, peptide length, or salts)
  • Formulation (excipients, concentration, buffering system, stability, aggregation control)
  • Manufacturing process (solid-phase synthesis steps, purification, refolding/handling, pegylation-like modifications if applicable)
  • Delivery device (cartridge, pen or injector mechanics) where claimed
  • Method of use (osteoporosis subtypes, hypoparathyroidism, chronic kidney disease-mineral bone disorder, diabetic-related indications)

---

Which parathyroid hormone analog drugs dominate sales and what is their patent expiration schedule?

Featured-snippet answer: The patent/launch calendar in this class centers on a small set of marketed analogs: teriparatide (and depot formulations in some jurisdictions), abaloparatide, and parathyroid hormone receptor agonist approaches. Patent timelines are multi-layered: composition claims usually outlast formulation and device/process claims.

Key marketed actives and commercial anchors

The commercial leadership and patent exposure typically concentrates on:

• Teriparatide (PTH 1-34; marketed as a daily injection; franchise also includes depot/long-acting related strategies in some geographies)
• Abaloparatide (PTH analog; marketed as a daily injection)
• PTH(1-84) analog pathways appear in adjacent “parathyroid hormone” discussions but are treated as different actives with separate IP estates

How exclusivity stacks in this class

For each marketed analog, exclusivity tends to be split across:

• Regulatory data exclusivity (product-specific)
• Patent terms (composition, method of use, formulation, process)
• Orphan/pediatric extensions where applicable
• Orange Book listings (where the product is listed and patents attach to NDA/BLA)

---

What patents protect teriparatide in the US and how many are typically listed in Orange Book?

Featured-snippet answer: Teriparatide’s estate is usually the most complex in this segment because it has matured into multiple formulation and method-of-use generations, with Orange Book coverage that tends to include composition, dosage regimen, and formulation/stability claims.

Patent estate pattern for teriparatide

Most common claim buckets:

1. Composition of matter
   • peptide sequence and related analogs, salts, and stabilized forms
2. Formulation and stability
   • concentration, pH range, buffer type, surfactant or stabilization excipients, aggregation/oxidation control
3. Method of use
   • osteoporosis subtypes (postmenopausal, high-risk, male osteoporosis in some filings)
4. Device and administration instructions
   • sometimes limited, but can appear via dosage form claims tied to cartridges/pens

Litigation and generic entry leverage

In practice, generic developers face a dual barrier:

• IP barriers: composition/formulation/process claims that constrain “design-around”
• Regulatory barriers: proving sameness for complex peptides plus bridging stability and immunogenicity considerations

Orange Book status: why it matters

Orange Book listings define what Paragraph IV or other patent challenges can target. In this class, even when a later-terminating formulation/process patent expires, earlier composition or method-of-use claims can block launch.

---

What patents protect abaloparatide and when does it lose exclusivity?

Featured-snippet answer: Abaloparatide’s protection typically spans composition plus method-of-use and formulation stability claims. The effective exit from exclusivity risk often happens only after the last enforceable Orange Book patent tied to the NDA expires or after a successful litigation/settlement path.

Typical coverage structure for abaloparatide

• Composition: active analog and pharmaceutically acceptable forms
• Formulation: solution characteristics and stability over intended shelf life
• Method-of-use: osteoporosis patient subsets and duration regimens

Generic entry risk mechanism

Even after regulatory exclusivity ends, a generic must:

• Address all enforceable patents listed for the product
• File via the applicable statutory pathway (for biologics, biosimilar pathway; for chemically treated products, ANDA-style approach)
• Either win litigation or enter under settlement terms

---

When does patent expiration allow generic teriparatide or abaloparatide launches and what is the key sequencing risk?

Featured-snippet answer: Launch timing is governed by the last-to-expire enforceable patent (often a composition or method-of-use claim). “Partial” expiries in formulation/process patents can reduce manufacturing constraints but still do not clear the statutory launch bar if any listed patent remains in force.

Sequencing logic used by entrants and litigators

1. Identify the last listed patent that can block approval.
2. Map whether each patent is:
   • composition, formulation, process, or method-of-use
3. Determine if any patents were:
   • asserted in litigation
   • settled with carve-outs
4. Translate expiry and any injunction/litigation stay rules into a practical launch window

Why sequencing creates commercial timing cliffs

In peptide analogs, formulation and process patents can expire earlier than composition, but entrants can still be forced to wait for composition or method-of-use claims to clear.

---

Which companies are challenging parathyroid hormone analog patents with Paragraph IV and what are typical outcomes?

Featured-snippet answer: Patent challenges in this segment are typically rare and concentrated around the most economically important product. Outcomes usually follow one of two patterns: (1) dismissal or unfavorable ruling that preserves the brand’s exclusivity, or (2) settlement that delays launch and can include “design-around” constraints.

What to expect from challenge dynamics

• Paragraph IV mechanisms apply to NDA-listed patents where the statutory pathway fits.
• For biologics-treated products, the biosimilar framework governs:
  • a different litigation posture
  • different exclusivity and interchangeability endpoints

---

What biosimilar risks exist for parathyroid hormone analogs and how does regulatory classification affect them?

Featured-snippet answer: Biosimilar risk depends on whether the product is regulated as a biologic and how the regulator classifies the active/route. For peptide analogs that are not treated as typical biologic drugs, “generic” routes may dominate, but the technical bar for high-fidelity peptide replication remains.

Classification drives the legal toolset

• If treated as a biologic: biosimilar development includes structural/functional characterization, immunogenicity considerations, and a distinct data package.
• If treated as a chemical/peptide NDA: generic-style development focuses on bioequivalence and formulation comparability with a statutory ANDA framework.

Why biosimilarity is not a quick substitute for “generic”

Even when the regulatory category looks permissive, entrants still must clear:

• stability, aggregation profile, and shelf-life
• immunogenicity risk
• bridging studies that regulators can treat as critical for approval

---

What formulations are protected by parathyroid hormone analog patents and how do they affect design-around?

Featured-snippet answer: Formulation patents typically protect buffer systems, pH set points, excipient selection, peptide concentration, and stability profiles. Design-around is constrained because changes can affect oxidation, deamidation, aggregation, and delivery performance.

Formulation claim themes across the class

• Buffer and pH range that maintains stability across the claimed shelf-life period
• Surfactant or stabilizer excipients that limit aggregation and adsorption
• Peptide concentration and container-closure interactions
• Lyophilized vs solution presentation if claimed
• Stability-inducing conditions and acceptance thresholds

Practical impact on launch strategy

Even if composition claims can be designed around, formulation/process patents can force:

• new stability programs
• new manufacturing verification
• delayed submission timelines

---

Which method-of-use patents affect osteoporosis and hypoparathyroidism indications for parathyroid hormone analogs?

Featured-snippet answer: Method-of-use claims shape the ability to market for specific patient subsets (high fracture risk, postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and chronic kidney disease-mineral bone disorder contexts). A generic may be approved but blocked from commercially targeting the claimed regimen.

Method-of-use claim categories

• Osteoporosis patient risk stratification
• Duration and dosing regimen
• Endpoints such as fracture reduction or bone mineral density improvements used to craft claim language
• Population-specific claims that can create carve-out marketing even when the product is approved

---

What manufacturing and process patents for peptide production can block generic parathyroid hormone analogs?

Featured-snippet answer: Process patents often cover synthesis steps, purification, and stabilization techniques specific to the peptide analog. These claims can be difficult to avoid because the molecule itself constrains many process choices.

Process claim themes

• Solid-phase synthesis protocols and purification parameters
• Handling steps that prevent oxidation and aggregation
• Refolding/refinement if applicable
• Sterile filtration, fill-finish, and container-closure process parameters
• In-process controls tied to impurity profiles

Litigation relevance

Process patents become leverage in settlement because challengers can argue invalidity while brands push to preserve the practical manufacturing barrier.

---

How does Orange Book status map to litigation risk for parathyroid hormone analog generics?

Featured-snippet answer: Orange Book patents determine which claims can be challenged and which patents block approval. In this class, brands typically list multiple patent types against the same NDA, increasing the number of hurdles for an entrant.

Orange Book-to-litigation mapping used by counsel

• If the NDA lists composition patents that expire later, the brand’s primary leverage is composition.
• If composition expires earlier, brands may rely on:
  • method-of-use patents
  • formulation/stability patents
  • device/dosage form patents
• Settlements often:
  • set launch dates
  • include non-attribution provisions
  • limit specific indications

---

What patent litigation has affected teriparatide or abaloparatide launch dates?

Featured-snippet answer: Litigation in this class typically targets formulation/process and method-of-use patents, with settlements used to delay launch and define carve-out indications.

Settlement-driven market outcomes

In peptide analogs, brand settlements usually aim to:

• preserve the “full label” period
• prevent early entry with alternative patient subset labels
• control competition timing by tying approval to a specific date rather than only patent expiry

How to interpret outcomes for investors

• A settlement close to expiry often signals:
  • high probability of early approval if patents are not fully enforceable
• A settlement far from expiry suggests:
  • stronger enforceability posture or willingness to pay to keep the market monopoly

---

What is the competitive landscape for parathyroid hormone analogs by country, and where are generic/biosimilar barriers highest?

Featured-snippet answer: Barriers are highest where:

• the patent estate is broad and recently amended
• courts enforce method-of-use and formulation claims strictly
• regulators require extensive comparability packages for peptides

Country-by-country considerations (high-level)

• US: Orange Book listing and NDA patent enforcement create multiple hurdles for entrants.
• EU: supplemental protection certificates and data protection can extend effective exclusivity.
• UK: SPCs and enforcement through UK courts or cross-border litigation can preserve barriers.
• Canada/Japan/Australia: patent linkage systems and data protection terms can delay generic entry.

---

Revenue exposure: which parathyroid hormone analogs have the highest sales-at-risk from patent expiry and generic entry?

Featured-snippet answer: Sales at risk concentrate where (1) the product is the class revenue leader and (2) the patent estate includes later-expiring method-of-use or formulation patents. In practice, daily injectable regimens sustain market share, making any “full label” clearance crucial.

Drivers of sales-at-risk in this class

• Competitive substitution within osteoporosis regimens
• Payer preference and formulary tiering
• Uptake in high-risk patient groups where method-of-use claims matter
• Supply continuity and device preference

---

Key Takeaways

• Patent estates for parathyroid hormone analogs are layered across composition, formulation/stability, process, and method-of-use claims, which makes “early expiry” of formulation or process insufficient to enable launch.
• Effective exclusivity and launch windows are determined by the last-to-expire enforceable Orange Book patent (US) and comparable national patent/data-protection extensions (EU/UK and others).
• Litigation and settlement history are central in predicting launch timing, with outcomes often defining both launch dates and label carve-outs.
• Market competition is constrained by peptide manufacturing precision and stability requirements, so even when regulatory pathways allow entry, IP and comparability constraints drive real-world delays.

FAQs

1. How many patent categories typically protect teriparatide in the US and which ones block generic approval first?
2. Do method-of-use claims for osteoporosis prevent label expansion even after patent expiry?
3. What formulation attributes of peptide analogs are most frequently claimed (buffer, pH, excipients, concentration)?
4. How does the regulatory classification (biologic vs peptide NDA) change the legal strategy for entrants?
5. What settlement terms are most common in peptide analog patent cases, and how do they translate into launch timing?

References

1. Not available.